Chemokine and cytokine levels in inflammatory bowel disease patients

Cytokine

Volumn 77, Issue , 2016, Pages 44-49

  Singh, Udai P ^a   Singh, Narendra P ^a   Murphy, E Angela ^a   Price, Robert L ^a   Fayad, Raja ^b   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemokine; Crohn's disease (CD); Cytokine; Inflammation; Inflammatory bowel disease (IBD); Ulcerative colitis (UC)

Indexed keywords

CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 16; INTERLEUKIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; ARTICLE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; LEUKOCYTE MIGRATION; MACROPHAGE MIGRATION; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; TISSUE INJURY; ULCERATIVE COLITIS; UNITED STATES; AGED; BLOOD; HELPER CELL; MACROPHAGE; METABOLISM; MIDDLE AGED; NEUTROPHIL;

ADULT; AGED; CHEMOKINES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; MALE; MIDDLE AGED; NEUTROPHILS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84946221448     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.10.008     Document Type: Article

References (48)

1. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
2. Selby W.S., Janossy G., Bofill M., Jewell D.P. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984, 25:32-40.
3. Powrie F., Leach M.W. Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Therap. Immunol. 1995, 2:115-123.
4. Hollander G.A., Simpson S.J., Mizoguchi E., Nichogiannopoulou A., She J., Gutierrez-Ramos J.C., et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995, 3:27-38.
5. Elson C.O., Sartor R.B., Tennyson G.S. Riddell RH Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
6. Monteleone G. Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut 1998, 43:735-736.
7. Sundaramoorthi R., Siedem C., Vu C.B., Dalgarno D.C., Laird E.C., Botfield M.C., et al. Selective inhibition of Src SH2 by a novel thiol-targeting tricarbonyl-modified inhibitor and mechanistic analysis by (1)H/(13)C NMR spectroscopy. Bioorgan. Med. Chem. Lett. 2001, 11:1665-1669.
8. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
9. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996, 379:821-823.
10. Ma Y., Ohmen J.D., Li Z., Bentley L.G., McElree C., Pressman S., et al. A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm. Bowel Dis. 1999, 5:271-278.
11. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001, 2:123-128.
12. Yoshie O., Imai T., Nomiyama H. Chemokines in immunity. Adv. Immunol. 2001, 78:57-110.
13. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52:145-176.
14. Zimmerman N.P., Vongsa R.A., Wendt M.K., Dwinell M.B. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14:1000-1011.
15. Kamada N., Hisamatsu T., Honda H., Kobayashi T., Chinen H., Takayama T., et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm. Bowel Dis. 2010, 16:568-575.
16. Zhang H., Ma L., Dong L.Q., Shu C., Xu J.L. Association of the macrophage migration inhibitory factor gene-173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene 2013, 526:228-231.
17. (-/-) mice. J. Immunol. 2003, 171:1401-1406.
18. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol. 1999, 155:331-336.
19. Shibahara T., Wilcox J.N., Couse T., Madara J.L. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gastroenterology 2001, 120:60-70.
20. -/- mice reconstituted with CD4+CD45RBhigh T cells. Eur. J. Immunol. 2001, 31:1465-1474.
21. Wurbel M.A., McIntire M.G., Dwyer P. Fiebiger E CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS ONE 2011, 6:e16442.
22. Grimm M.C., Elsbury S.K., Pavli P., Doe W.F. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J. Leukoc. Biol. 1996, 59:804-812.
23. Reinecker H.C., Loh E.Y., Ringler D.J., Mehta A., Rombeau J.L., MacDermott R.P. Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 1995, 108:40-50.
24. Seegert D., Rosenstiel P., Pfahler H., Pfefferkorn P., Nikolaus S., Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001, 48:326-332.
25. Kunkel E.J., Campbell D.J., Butcher E.C. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 2003, 10:313-323.
26. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 1996, 184:241-251.
27. Pizarro T.T., Arseneau K.O., Cominelli F. Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am. J. Physiol. - Gastro Liver Physiol. 2000, 278:G665-G669.
28. Yuan Y.H., ten Hove T., The F.O., Slors J.F., van Deventer S.J., Te Velde A.A. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm. Bowel Dis. 2001, 7:281-286.
29. Singh U.P., Singh S., Weaver C.T., Iqbal N., McGhee J.R., Lillard J.W. IFN-g-inducible chemokines enhance adaptive immunity and colitis. J. Interferon Cytok. Res. 2003, 23:2000-2009.
30. Singh U.P., Venkataraman C., Singh R., Lillard J.W. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr., Metab. Immune Disorders Drug Targets 2007, 7:111-123.
31. Hanai H., Takeuchi K., Iida T., Kashiwagi N., Saniabadi A.R., Matsushita I., et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 2004, 49:1438-1443.
32. Verspaget H.W., Pena A.S., Weterman I.T., Lamers C.B. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 1988, 29:223-228.
33. Mee A.S., Jewell D.P. Monocytes in inflammatory bowel disease: monocyte and serum lysosomal enzyme activity. Clin. Sci. (Lond.) 1980, 58:295-300.
34. Matsushima K., Larsen C.G., DuBois G.C., Oppenheim J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 1989, 169:1485-1490.
35. Mazzucchelli L., Hauser C., Zgraggen K., Wagner H.E., Hess M.W., Laissue J.A., et al. Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J. Pathol. 1996, 178:201-206.
36. Shibata W., Maeda S., Hikiba Y., Yanai A., Ohmae T., Sakamoto K., et al. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 2007, 179:2681-2685.
37. Grose R.H., Howarth G.S., Xian C.J., Hohmann A.W. Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse. J. Gastroenterol. Hepatol. 2001, 16:1228-1234.
38. Ogawa A., Andoh A., Araki Y., Bamba T., Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 2004, 110:55-62.
39. Khan W.I., Motomura Y., Wang H., El-Sharkawy R.T., Verdu E.F., Verma-Gandhu M., et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am. J. Physiol. Gastro Liver Physiol. 2006, 291:G803-G811.
40. Kim C.S., Kang J.H., Cho H.R., Blankenship T.N., Erickson K.L., Kawada T., et al. Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. Inflamm. Res: Off. J. Eur. Histamine Res. Soc. 2011, 60:889-895.
41. Nishimura M., Kuboi Y., Muramoto K., Kawano T., Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann. N.Y. Acad. Sci. 2009, 1173:350-356.
42. Saruta M., Yu Q.T., Avanesyan A., Fleshner P.R., Targan S.R., Papadakis K.A. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J. Immunol. 2007, 178:3293-3300.
43. Wang P., Lu Y.Q., Wen Y., Yu D.Y., Ge L., Dong W.R., et al. IL-16 induces intestinal inflammation via PepT1 upregulation in a pufferfish model: new insights into the molecular mechanism of inflammatory bowel disease. J. Immunol. 2013, 191:1413-1427.
44. Gaetke L.M., Oz H.S., de Villiers W.J., Varilek G.W., Frederich R.C. The leptin defense against wasting is abolished in the IL-2-deficient mouse model of inflammatory bowel disease. J. Nutr. 2002, 132:893-896.
45. Reimund J.M., Wittersheim C., Dumont S., Muller C.D., Kenney J.S., Baumann R., et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996, 39:684-689.
46. Casini-Raggi V., Kam L., Chong Y.J., Fiocchi C., Pizarro T.T., Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 1995, 154:2434-2440.
47. Parronchi P., Romagnani P., Annunziato F., Sampognaro S., Becchio A., Giannarini L., et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 1997, 150:823-832.
48. Sasaki S., Yoneyama H., Suzuki K., Suriki H., Aiba T., Watanabe S., et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur. J. Immunol. 2002, 32:3197-3205.